DESTINY-Breast06
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
- NCT04494425 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built an HCP commentary report on DESTINY-Breast06 (trastuzumab deruxtecan in hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 40 newest of 517 indexed sources (May 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- How to sequence trastuzumab deruxtecan with other antibody–drug conjugates
- Whether to use chemotherapy or an antibody–drug conjugate after endocrine therapy
- How trastuzumab deruxtecan compares with newer antibody–drug conjugates
Also discussed: antibody–drug conjugate toxicity profiles, HER2 testing and expression heterogeneity.
Indexed commentary on DESTINY-Breast06 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 196 | |
| YouTube | 170 | |
| Podcasts | 131 | |
| Bluesky threads | 16 | |
| X videos | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan; Capecitabine; Paclitaxel; Nab-Paclitaxel
- Arms
- Trastuzumab deruxtecan · Experimental
- Standard of Care · Active comparator
- Enrollment
- 866
- Primary outcomes
- Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Jul 24, 2020
- Primary completion
- Mar 18, 2024
- Results posted
- Yes
- Registry record
- NCT04494425 · updated Mar 4, 2026
Publications
linked from the registry- Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Levy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. PubMed 39282896
- Tarantino P, Tolaney SM, Curigliano G. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol. 2023 Oct;34(10):949-950. doi: 10.1016/j.annonc.2023.07.003. Epub 2023 Jul 26. No abstract available. PubMed 37499870